Jazz Pharmaceuticals Secures Conditional EU Approval for Ziihera
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has achieved a significant milestone with the receipt of conditional marketing authorization from the European Commission for Ziihera (zanidatamab). This innovative bispecific antibody targets the HER2 protein and is designated for monotherapy in adults suffering from unresectable locally advanced or metastatic HER2-positive biliary tract cancer (BTC) that has previously been treated with at least one line of systemic therapy.
Biliary tract cancers, which comprise gallbladder cancer and cholangiocarcinoma, are aggressive types of cancer often detected at advanced stages. Unfortunately, most patients receive a diagnosis when curative surgical options are not viable. Within the global demographic of BTC patients, approximately 26% are identified as HER2-positive, which correlates with poorer prognoses compared to those with HER2-negative cancers.
Ziihera stands out as the first HER2-targeted therapy to receive conditional approval for HER2-positive BTC in the European Union. This critical approval paves the way for further validation of its clinical benefits through ongoing studies, notably the Phase 3 HERIZON-BTC-302 trial. This trial aims to assess the effectiveness of zanidatamab in combination with standard therapies against standard treatments alone in the first-line setting for patients with HER2-positive BTC.
Dr. Arndt Vogel, a leading consultant and professor in the field, emphasized the profound impact this treatment can have on patients facing bleak prognoses after first-line therapies. With limited options available, Zanidatamab’s potential to offer targeted responses and manageable safety profiles is a breakthrough for individuals battling this challenging disease.
The European Commission's decision derives from data collected through the Phase 2b HERIZON-BTC-01 trial, which meticulously studied Ziihera in 87 patients diagnosed with previously treated HER2-positive BTC. Results indicate an impressive confirmed overall response rate (cORR) of 41.3%, showcasing both complete and partial responses, alongside a median duration of response reaching up to 14.9 months and an overall survival median of 15.5 months.
In a significant subgroup analysis, patients with IHC 3+ tumors showed an even higher cORR of 51.6% with a median overall survival of 18.1 months. The recommended Ziihera treatment regimen is set at a dosage of 20 mg/kg administered every two weeks until disease progression occurs or adverse reactions become intolerable.
The safety evaluations of zanidatamab indicated that while most patients experienced manageable side effects, including diarrhea and fatigue, serious adverse reactions occurred in a notable percentage, necessitating ongoing monitoring and support.
Robert Iannone, M.D., expressed pride in this approval, underscoring the urgency for innovative treatments in rare gastrointestinal cancers. The decision reflects not only substantial data from the HERIZON-BTC-01 trials but also the company's commitment to advancing therapies aimed at significant unmet medical needs.
In recent years, there has been an observable increase in the incidence of biliary tract cancers among younger populations, contributing to both social and economic pressures. Ziihera provides a vital alternative to chemotherapy for eligible patients at advanced stages of the disease.
The authorization afforded by the European Commission encompasses all member countries within the EU as well as additional territories including Iceland, Norway, and Liechtenstein. As research continues, Jazz Pharmaceuticals actively recruits for the Phase 3 trial, exploring further applications of zanidatamab across various HER2-expressing tumors.
About Ziihera: Ziihera (zanidatamab) is characterized by its dual targeting of HER2 receptors, effectively promoting receptor internalization and inhibiting tumor growth through several mechanisms including antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. These properties demonstrate the antibody’s capability to induce tumor cell death and support its future utility in different solid tumors expressing HER2.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc, trading under Nasdaq: JAZZ, is a biopharmaceutical innovator committed to transforming patient lives through groundbreaking medicines focused on significant medical needs. With a diverse portfolio, its research endeavors sprawl across neuroscience and oncology, aiming to offer solutions specifically tailored to enhance patient well-being.
Frequently Asked Questions
What is Ziihera (zanidatamab)?
Ziihera is a bispecific antibody that targets HER2, uniquely designed to treat advanced HER2-positive biliary tract cancer.
Why is the approval of Ziihera significant?
This approval is pivotal as it is the first HER2-targeted therapy authorized in the European Union specifically for HER2-positive biliary tract cancer, offering hope for better patient outcomes.
How effective is Ziihera based on clinical trials?
Clinical trials have shown Ziihera has a confirmed overall response rate of 41.3%, with encouraging median overall survival statistics.
What does the treatment regimen for Ziihera include?
The treatment involves a dose of 20 mg/kg administered intravenously every two weeks until the disease progresses or adverse events become unacceptable.
Who is affected by biliary tract cancers?
Biliary tract cancers predominantly affect adults, with increasing incidence rates seen in individuals under 60, highlighting a growing health concern.
